The scale-X bioreactor is an intensified and chained bioprocessing platform for viral developers and manufacturers. It multiplies product yield and reduces operational volumes per cleanroom surface area compared to traditional technology.Read article "scale-X™ bioreactor demonstrates superior productivity for vaccines and gene therapy"
Partnership will optimize manufacturing of extracellular vesicles (EVs) using scalable and continuous bioprocessing technologies to propel the commercialization of regenerative therapies at affordable costs.Read article "Partnership with RoosterBio to advance scalable & continuous exosomes manufacture"
Launched in April 2019, The scale-X™ carbo is an intermediate scale system designed for rapid process development and GMP manufacturingRead article "Going from process development to clinical manufacturing has never been so easy"
The two companies announce a worldwide strategic partnership to develop and optimize platform processes using best-in-class technologies for the production of custom viral vectors.Read article "New strategic partnership with VectorBuilder for optimized custom viral vector production"
The scale-X carbo will be featured at the Dublin facility for biopharma industry researchers and personnel to gain hands-on experience with this and other leading next-generation, enabling biomanufacturing technologiesRead article "NIBRT adds scale-X™ carbo system for upstream viral manufacturing demonstrations and training"
Felix Kasper, Head of Bioprocess & Field Services of Univercells Technologies discusses the launch of Integrated Services.Read article "Integrating Services with innovative technologies to enhance bioprocesses"
In his new role, Mathias will take the company through the next stage of strategic development and growthRead article "Mathias Garny appointed as CEO of Univercells Technologies"
Ology Bioservices is a full-service Contract Development Manufacturing Organization (CDMO) serving both government and commercial clients, specializing in biologic drug substance manufacturing from early-stage through commercial product. The company is continuously evaluating new […]Read article "CDMO Ology Bioservices adopts the scale-X™ to face vaccine manufacturing challenges"
New generation NevoLine™ platform for intensified & automated virus manufacturingRead article "The NevoLine™ Upstream Platform for intensified & automated virus manufacturing"
Experts Opinion in BioPharm International “The development of breakthrough fixed-bed bioreactors bring new opportunities in readily developing and scaling adherent platforms as an alternative to stirred-tanks reactors”. Our Product Manager […]Read article "Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines"
The scale-X™ bioreactor range and the NevoLine™ platform for an intensified AAV and Lentiviral vectors manufacturingRead article "Building capacity for gene therapy production"
Exyte and Univercells Technologies are announcing a global partnership for optimized construction of modular standardized and flexible GMP manufacturing facilities for vaccines.Read article "New partnership with Exyte for rapid deployment of vaccine production plants in the wake of the COVID-19 pandemic"
Univercells Technologies, a global provider of next-generation bioprocess technologies, launches today. Under this new brand, the company will focus on the commercialization of the product portfolio and will explore new technology developments […]Read article "Launch of Univercells Technologies for intensified, automated technologies"
The investment will be deployed in a newly created subsidiary of Univercells focused on accelerating the industrialization and commercialization of Univercells’ manufacturing technologiesRead article "€50M investment from KKR platform to accelerate the commercialization of technologies portfolio"
Bench-scale automated cell culture system featuring the scale-X single-use fixed-bed bioreactor offering 10 to 30 m² growth surface.Read article "Introducing the single-use scale-X™ carbo bioreactor system"
Univercells and consortium partner Batavia Biosciences have been awarded a $4 million grant extension by the Bill & Melinda Gates Foundation to scale up their low-cost polio vaccine manufacturing technology.Read article "Introducing the NevoLine™ sIPV platform"
Inauguration of new facility for the development and production of our technology solutions in Nivelles, BelgiumRead article "Inauguration of our new Equipment Design Center"
Univercells Receives $12 Million Grant to Develop Breakthrough Vaccine Manufacturing PlatformRead article "$12 million grant to develop breakthrough vaccine manufacturing platform"